VivaVision Biotech Receives Positive FDA Feedback for VVN461LD Trial in Eye Inflammation Treatment VivaVision Biotech has received encouraging preliminary comments from the FDA regarding its VVN461LD treatment for post-operative eye inflammation, simplifying the trial process.

VivaVision Biotech Receives Positive FDA Feedback for VVN461LD Trial in Eye Inflammation Treatment #China #FDA #VivaVision #Wenzhou #VVN461LD